Objective-Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily of cytokines. TWEAK binds and activates the Fn14 receptor, and may regulate apoptosis, inflammation, and angiogenesis, in different pathological conditions. We have evaluated the effect of exogenous TWEAK administration as well as the role of endogenous TWEAK on proinflammatory cytokine expression and vascular and renal injury severity in hyperlipidemic ApoE-knockout mice. Methods and Results-ApoE Ϫ/Ϫ mice were fed with hyperlipidemic diet for 4 to 10 weeks, then randomized and treated with saline (controls), TWEAK (10 g/kg/d), anti-TWEAK neutralizing mAb (1000 g/kg/d), TWEAK plus anti-TWEAK antibody (10 g TWEAK ϩ1000 g anti-TWEAK/kg/d), or nonspecific IgG (1000 g/kg/d) daily for 9 days. In ApoE Ϫ/Ϫ mice, exogenous TWEAK administration in ApoE Ϫ/Ϫ mice induced activation of NF-B, a key transcription factor implicated in the regulation of the inflammatory response, in vascular and renal lesions. Furthermore, TWEAK treatment increased chemokine expression (RANTES and MCP-1), as well as macrophage infiltration in atherosclerotic plaques and renal lesions. These effects were associated with exacerbation of vascular and renal damage. Conversely, treatment of ApoE Ϫ/Ϫ mice with an anti-TWEAK blocking mAb decreased NF-B activation, proinflammatory cytokine expression, macrophage infiltration, and vascular and renal injury severity, indicating a pathological role for endogenous TWEAK. Finally, in murine vascular smooth muscle cells or tubular cells, either ox-LDL or TWEAK treatment increased expression and secretion of both RANTES and MCP-1. Furthermore, ox-LDL and TWEAK synergized for induction of MCP-1 and RANTES expression and secretion. Conclusion-Our results suggest that TWEAK exacerbates the inflammatory response associated with a high lipid-rich diet. TWEAK may be a novel therapeutic target to prevent vascular and renal damage associated with hyperlipidemia.
A therosclerosis is currently described as an inflammatory disease given that the main components of chronic inflammation are present in this process: cell recruitment, proliferation, neovascularization, and sclerosis. 1 Vascular lesions are caused by inflammatory and fibroproliferative responses to injury of the endothelium and vascular smooth muscle cells (VSMCs). Interaction between members of the tumor necrosis factor (TNF) superfamily and their receptors elicits diverse biological actions that participate in atherosclerosis development. These responses include the expression of adhesion molecules, proinflammatory cytokines, matrix metalloproteinases, and tissue factor, which are known to increase plaque instability. One of these members is the TNF-like weak inducer of apoptosis (TWEAK/TNFS12), which has different biological functions, including induction of inflammation, angiogenesis, activation of cell growth, and stimulation of apoptosis. [2] [3] The receptor of this protein is TWEAKR/Fn14, the smallest reported member of the TNF superfamily. 4 TWEAK and Fn14 are expressed in different cell types, including endothelial and VSMCs. 5 In addition, TWEAK/Fn14 interaction induces the secretion of proinflammatory chemokines such as interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) in different cell types. [2] [3] Both TWEAK and Fn14 have been detected in the diseased vessel wall, implicating this pathway in atherosclerotic plaque progression. 6 -7 
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A growing body of evidence indicates that chronic kidney disease (CKD) is frequently associated with cardiovascular disease (CVD), especially atherosclerosis, which constitutes one of the major causes of morbidity and mortality in CKD. 8 Atherosclerosis influence the progression of renal disease, implying that deterioration of renal function is likely provoked by atherogenic factors, such as hyperlipidemia. 9 Lipid abnormalities often accompany and exacerbate renal injury severity, 10 and hyperlipidemia is considered an independent risk factor for both renal and cardiovascular diseases. 11 It has been shown that hyperlipidemia is associated with formation of oxidized low-density lipoprotein (ox-LDL), increased oxidative stress, and renal inflammation, 12 changes that may compromise renal function. Both TWEAK and its receptor, Fn14, are present at relatively low levels in healthy adult kidney and highly induced after injury. [13] [14] Although different articles have reported the proinflammatory actions of TWEAK/Fn14 interaction in both VSMCs and renal cells in vitro, no study has been reported in the context of harmful environmental conditions. For these reasons, our aim was to investigate the effect of systemic TWEAK injection on vascular (early and advanced) atherosclerotic lesions and renal injury severity in ApoE knockout mice in the context of a hyperlipidemic status. Conversely, we investigated the role of the endogenous TWEAK pathway in atherosclerotic disease. Furthermore, we have analyzed the effect of oxidized-LDL (ox-LDL) or TWEAK alone and their combination on proinflammatory cytokines expression and secretion in VSMCs and renal tubular epithelial cells in vitro to analyze the potential synergistic interactions between both stimuli on inflammatory responses.
Methods

Reagents
RPMI-1640, DMEM, penicillin, streptomycin, and trypsin-EDTA were obtained from BioWhittaker. FBS was from Gibco. Recombinant human TWEAK was from Alexis. A blocking murine anti-TWEAK mouse monoclonal antibody (clone P2D10) was generated in TWEAK Ϫ/Ϫ mice and cross-reacts with human TWEAK. The generation of mAB and TWEAK blocking activity was previously described. 15 This antibody was generously gift by Biogen Idec (Cambridge, Mass).
Cell Cultures
The murine proximal tubular epithelial cell line (MCT) was cultured in RPMI 1640, 10% heat-inactivated fetal bovine serum (FBS), 2 mmol/L glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin, in 5% CO2 at 37°C. Murine ApoE Ϫ/Ϫ VSMCs were cultured in DMEM containing 10% FBS, 2 mmol/L glutamine, 100U/mL penicillin, and 100 g/mL streptomycin. Quiescent cells were stimulated with human recombinant TWEAK and/or oxidized LDL.
Isolation and Oxidation of LDL
Human LDL were isolated from a fresh plasma pool by sequential ultracentrifugation (2 hour at 405 000g and 4°C) immediately after separation of plasma at density between 1.019 and 1.063 and after VLDL isolation at dϽ1.019 using a Beckman model LE-70 ultracentrifuge with a Type NVT65 rotor (Beckman). The LDL fraction was dialyzed for 24 hours at 4°C with 3 changes of PBS, containing 0.01% EDTA for the first and only PBS for the 2 others. LDL protein content was determined by using the method of Bradford. LDL oxidation was carried out by incubating 200 g/mL LDL protein with 5 mol/L CuSO4 in 1.0 mL PBS medium at 37°C for 120 minutes. The reaction was stopped by adding 100 mol/L EDTA at 4°C and immediately dialyzed again to eliminate EDTA. Before experiments, oxidized-LDL was sterilized by passage through a 0.22-mm Millipore filter.
Quantitative Reverse Transcription-Polymerase Chain Reaction
Total RNA from cells or tissues was isolated by Trizol (Invitrogen UK) and quantified by absorbance at 260 nm. 14 One g RNA was reverse transcribed with High Capacity cDNA Archive Kit (Applied Biosystems). Real-time PCR reactions were performed on an ABI Prism 7500 PCR system (Applied) according to manufacturer's protocol using the DeltaDelta Ct method. 16 Expression levels are given as ratios to GAPDH. Predeveloped primer and probe assays were obtained for murine GAPDH, RANTES, and MCP-1 (Applied).
Animal Model
In one experimental design for the study of early atherosclerotic lesions, 32 male ApoE Ϫ/Ϫ mice (12 weeks of age; Jackson Laboratories, Bar Harbor, Maine) were fed on a hyperlipidemic diet (21.2% fat [0.15% cholesterol] ϩ 16.7% proteins) during 4 weeks, then randomized in 4 groups: mice injected i.p. with saline (controls, nϭ8), human recombinant TWEAK (10 g/kg/d, nϭ9) alone or in combination anti-TWEAK mAb (10 g TWEAK ϩ1000 g anti-TWEAK/kg/d, nϭ8), or anti-TWEAK mAb alone (1000 g anti-TWEAK/kg/d, nϭ7) daily for 9 days. In all animals which received TWEAK in combination with anti-TWEAK mAb, the anti-TWEAK mAb was injected 15 minutes before TWEAK injection. The data for the anti-TWEAK mAb treated group were generated in a separate experiment than the data presented for the other 3 groups.
In a second experimental design for the study of advanced atherosclerotic lesions, 24 male ApoE Ϫ/Ϫ mice (16 weeks of age) were fed on a hyperlipidemic diet during 10 weeks then randomized in 4 groups: mice injected i.p. with saline (controls, nϭ6), human recombinant TWEAK (10 g/kg/d, nϭ6), anti-TWEAK mAb (1000 g anti-TWEAK/kg/d, nϭ6), or nonspecific IgG (1000 g/kg/d, nϭ6) daily for 9 days.
The dose of TWEAK was chosen based on prior in vivo studies, 14 and the dose of anti-TWEAK mAb was chosen to be 100-fold in excess of the TWEAK dose. Blood was collected into EDTA-coated tubes and plasma was stored at Ϫ80°C until used. Cholesterol was tested in serum samples (Thermo Trance). Anesthetized mice were saline-perfused. Aorta was OCT-embedded and frozen for immunohistochemistry. One kidney from each mouse was fixed in 4% paraformaldehyde, embedded in paraffin, and used for immunohistochemistry. The other kidney was snap-frozen in liquid nitrogen for RNA and protein studies. These studies were performed in accordance with the European Union normative and were approved by the ethical committee of our institution.
Renal and Vascular Histopathologic Studies and Immunohistochemistry
To assess histological changes, paraffin-embedded kidneys were cross-sectioned into 2-m-thick pieces and Masson trichrome staining scored for renal injury by an outside pathologist (J.B.) blinded to the nature of the samples. Tissue sections were scored according to the extent of glomerular changes (hypertrophy, hypercellularity, mesangial expansion, and fibrosis) and tubular/interstitial damage (loss of brush border, cell desquamation, tubular dilatation, signs of regeneration, perivascular infiltration, and interstitial fibrosis) on a 0 to 3 scale as follows: 0ϭabsent; 1ϭmild; 2ϭmoderate; 3ϭsevere. 14 Aortic roots were frozen in OCT, and serial 4-m sections were stained with Oil red O/hematoxylin and lesion size was quantified by computerized morphometry. 17 Collagen content was stained with picrosirious red. Immunohistochemistry was carried out as previously described. 18 Primary antibodies were goat anti-TWEAK polyclonal antibody (1/50; R&D systems), rabbit anti-Fn14 polyclonal antibody (1/50; Cell Signaling), goat polyclonal anti-MCP-1 (1:100, Santa Cruz), rabbit polyclonal anti-RANTES (1:10, Chemicon), rat polyclonal anti-F4/80 antigen (1:50, Serotec), rat monoclonal anti-MOMA-2 (1:800, Sero-tec), rat monoclonal anti-CD4 ϩ (1:10, Pharmingen), and rat monoclonal anti CD8A ϩ . Donkey antigoat biotin, donkey antirabbit biotin, and goat antirat biotin (Amersham) were used as secondary antibodies. ABComplex/HRP was then added and sections were stained with 3,3-diaminobenzidine (DAKO), counterstained with hematoxylin, and mounted in Pertex (Medite). Sections were counterstained with Carazzi hematoxylin. Results were expressed as % positive area versus total area of Collagen, MCP-1, RANTES, and MOMA-2 staining in 20 randomly selected fields (ϫ100) per sample. Quantification of F4/80ϩ-stained cells was made by determining the total number of positive cells/total number of cells in 20 randomly chosen fields (ϫ100). Computer-assisted morphometric analysis was performed with the Image-Pro Plus software (version 1.0 for Windows). Samples from each animal were examined in a blinded manner.
Southwestern Immunohistochemistry
This technique was developed to detect the in situ distribution and DNA-binding activity of transcriptional factors. 19 NF-B consensus oligonucleotide was digoxigenin labeled with a 3Ј-terminal transferase (Roche). Paraffin-or OCT-embedded tissue sections were fixed in 0.5% paraformaldehyde and incubated with 0.1 mg/mL DNase I. The DNA binding reaction was performed by incubation with 50 pmol of the labeled DNA probe in buffer containing 0.25% BSA and 1 g/mL poly (dI-dC). The sections were then incubated with alkaline phosphatase-conjugated antidigoxigenin Ab, and colorimetric detection was performed as described. Preparations without probe were used as negative controls, and an excess of unlabeled probe was used to test the specificity of the technique. Results are expressed as % positive nuclei versus total nuclei to evaluate NF-B activation.
ELISA and Lipid Determinations
Concentration of MCP-1 and RANTES in the supernatants of the cell cultures were determined by ELISA (BD Pharmingen and Bender MedSysterms, respectively) following the manufacter's instructions. Serum cholesterol concentrations were determined by using Cholesterol reactive Infinity (TR13421; Sigma diagnostics). Serum concentration of TWEAK (Bender MedSystem) were determined by using ELISA following the manufacturer's instructions. ELISA was not impacted by the presence of anti-TWEAK mAb P2D10 (not shown). In addition, serum concentrations of anti-TWEAK mAb were determined using an ELISA in which mouse anti-TWEAK mAb binds to recombinant human TWEAK coated on plates.
Statistics
Statistical analysis was performed using SPSS 11.0 statistical software. Results are expressed as meanϮSEM. Significance at the PϽ0.05 level was assessed by Student t test for 2 groups of data and ANOVA for 3 or more groups. Experiments were replicated 3 times for each incubation period. Differences were considered significant at a value PϽ0.05.
Results
TWEAK Aggravates Vascular and Renal Damage
First of all, we have observed that both TWEAK and its receptor, Fn14, are expressed in atherosclerotic plaques and aortas from ApoE Ϫ/Ϫ mice (supplemental Figure I , available online at http://atvb.ahajournals.org). Animals from the different groups showed a hyperlipidemic profile without significant differences in cholesterol plasma concentration, indicating that TWEAK or anti-TWEAK neutralizing antibody injection did not affect the lipid metabolism (Table) . Body weights were unaltered between different groups of animals (Table) . As compared to controls, TWEAK plasma levels were significantly higher in mice injected with TWEAK alone or TWEAKϩanti-TWEAK (Table) . In hyperlipidemic ApoE Ϫ/Ϫ mice, TWEAK injection increased atherosclerotic lesion size in the aortic root as compared with control animals (502Ϯ31 versus 302Ϯ20, m 2 ϫ10 3 ; PϽ0.001; Figure 1A ). Furthermore, TWEAK injection aggravates renal damage in ApoE Ϫ/Ϫ mice (glomerular score: 2.05Ϯ0.16 versus 1.35Ϯ0.52, PϽ0.01; and tubular score: 1.71Ϯ0.38 versus 1.04Ϯ0.59, PϽ0.05; Figure 1B ). To confirm that TWEAK injection is responsible to the augmentation of vascular and renal damage, ApoE Ϫ/Ϫ mice were treated with TWEAK plus anti-TWEAK neutralizing antibody. TWEAK plus anti-TWEAK mAb-injected mice showed a reduction in both atherosclerotic lesion size and renal damage (335Ϯ17 versus 502Ϯ80; m 2 ϫ10 3 ; PϽ0.001; glomerular score: 0.91Ϯ0.58 versus 2.05Ϯ0.16, PϽ0.01; and tubular score: 0.61Ϯ0.62 versus 1.71Ϯ0.38, PϽ0.05) as compared with TWEAK alone treated animals ( Figure 1A and 1B ). Furthermore, after treatment with anti-TWEAK alone a significant reduction was observed in renal damage as compared with the control group (glomerular score: 0.58Ϯ0.35 versus 1.35Ϯ0.52; PϽ0.05; tubular score: 0.48Ϯ0.12 versus 1.04Ϯ0.59; PϽ0.05), and a small reduction observed in vascular damage although the latter was not significant (240Ϯ13 versus 302Ϯ20; m 2 ϫ10 3 ; N.S.; Figure 1A and 1B). 
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A trend to a diminution in collagen content was observed in TWEAK-injected mice compared with control animals (9.71Ϯ2.92% collagen/intima versus 14.35Ϯ1.07%; N.S.). No changes in collagen content were observed after treatment with anti-TWEAK alone or in combination with TWEAK as compared to control animals ( Figure 1C ).
TWEAK Induces Inflammatory Response and Macrophage Recruitment in Both Atherosclerotic Lesions and Kidney
TWEAK injection upregulated protein expression of chemokines such as RANTES (16.7Ϯ3.9% versus 5.0Ϯ1.1%, PϽ0.05) and MCP-1 (23.5Ϯ3.3% versus 5Ϯ0.9%, PϽ0.01) in atherosclerotic lesions present in the aortic root of ApoE Ϫ/Ϫ mice (Figure 2A ). In the same way, kidney protein expression of these chemokines was increased after TWEAK injection (RANTES [23.8Ϯ4.3% versus 9.1Ϯ1.1%, PϽ0.05] and MCP-1 [13.0Ϯ3.3% versus 6.7Ϯ1.1%, PϽ0.05]). These chemokines were localized to the tubular epithelium ( Figure 2B ).
Anti-TWEAKϩTWEAK significantly diminished the effect of TWEAK treatment with respect to both RANTES and MCP-1 protein expression in atherosclerotic plaques (1.7Ϯ0.6% versus 16.7Ϯ3.9%; PϽ0.05; 3.9Ϯ1.1% versus 23.5Ϯ3.3%; PϽ0.01, respectively) and in the kidney (6.8Ϯ2.5% versus 23.8Ϯ4.3%; PϽ0.05; and 6.1Ϯ2.5% versus 13.0Ϯ3.3%; PϽ0.05; respectively, Figure 2A and 2B). Furthermore, treatment with anti-TWEAK mAb alone diminished both RANTES and MCP-1 expression in atherosclerotic plaques (1.1Ϯ0.5; PϽ0.05; 2.8Ϯ0.7; PϽ0.05 respectively) and in the kidney (3.4Ϯ1.1 versus 9.1Ϯ1.1; PϽ0.05; 1.4Ϯ1.8 versus 6.7Ϯ1.1; PϽ0.05) compared with control animals (Figure 2A and 2B) .
Next, we evaluated the macrophage content in both atherosclerotic lesions and kidneys. Macrophage infiltration was increased in atherosclerotic plaques of TWEAK-injected ApoE Ϫ/Ϫ compared with control animals (50.5Ϯ4.5% versus 11.9Ϯ2.6%, PϽ0.001; Figure 3A ). Renal macrophage infiltration was also augmented after systemic TWEAK injection (5.7Ϯ0.7% versus 2.1Ϯ0.3%, PϽ0.001; Figure 3B ). Increment of TWEAK-induced macrophage infiltration was reduced after anti-TWEAK mAb cotreatment in atherosclerotic plaques (13.6Ϯ2.2% versus 50.5Ϯ4.5%, PϽ0.001) and in the kidney (1.9Ϯ0.4% versus 5.7Ϯ0.7%, PϽ0.001; Figure 3A and 3B). Treatment with anti-TWEAK alone also diminished macrophage infiltration in atherosclerotic plaques (6.9Ϯ0.8% versus 11.9Ϯ2.6%; PϽ0.05) and in the kidney (0.9Ϯ0.4% versus 2Ϯ0.3; PϽ0.05) as compared with control animals. The analysis of the presence of T lymphocytes in atherosclerotic plaques revealed a trend to higher numbers of CD4 ϩ -positive cells in animals treated with TWEAK compared with controls (34.6Ϯ8.9 versus 20Ϯ4.7; Pϭ0.17). Treatment with anti-TWEAK mAb plus TWEAK diminished the presence of CD4 ϩ cells in atherosclerotic lesions compared with TWEAK alone (9.4Ϯ3.1 versus 34.6Ϯ8.9; PϽ0.05; supplemental Figure IIA) . Moreover, injection of anti-TWEAK alone also reduced CD4 ϩ cells in vascular lesions compared with control animals (6.2Ϯ4.2 versus 20Ϯ4.7; PϽ0.05). No differences were observed in CD8 ϩpositive cells after TWEAK administration. (supplemental Figure IIA) . However, anti-TWEAK diminished the number of CD8 ϩ positive cells (supplemental Figure IIA) .
TWEAK Induces NF-B Activation in the Atherosclerotic Lesions and Kidney
NF-B is a key nuclear factor involved in proinflammatory responses. TWEAK injection significantly increased NF-B activation in atherosclerotic lesions (18.2Ϯ6.1% versus 5.4Ϯ1.4%, PϽ0.005) and in the kidney (21.7Ϯ4.3% versus 7.8Ϯ2.5%; PϽ0.01) in comparison with control animals ( Figure 3A and 3B) . Furthermore, anti-TWEAK neutralizing antibody prevented TWEAK-induced NF-B activation in both atherosclerotic plaques (2.8Ϯ1.6 versus 18.2Ϯ6.1, PϽ0.005) and in the kidney (5.2Ϯ2.3% versus 21.7Ϯ4.3%; PϽ0.01). Treatment with anti-TWEAK antibody alone also diminished NF-B activation in both atherosclerotic plaques (1.8Ϯ0.5 versus 5.4Ϯ1.4%, PϽ0.005) and in the kidney (3.5Ϯ0.8 versus 7.8Ϯ2.5;PϽ0.05) as compared with control animals.
TWEAK Promotes Severity of Advanced Atherosclerotic Lesions
To analyze the effect of TWEAK injection in advanced atherosclerotic lesions, 16-week-old mice were fed with a hyperlipidemic diet during 10 weeks. As expected, animals from the different groups showed similar body weight and hyperlipidemic profile without differences in cholesterol levels (Table) . As compared with controls, TWEAK plasma levels were increased in animals injected with TWEAK alone. TWEAK injection also aggravated atherosclerotic lesion size in the aortic root as compared with control animals (714Ϯ40 versus 453Ϯ22; m 2 ϫ10 3 ; PϽ0.001; Figure 4 ). Treatment with anti-TWEAK alone diminished atheroscle- rotic lesions size compared with control animals (313Ϯ16 versus 453Ϯ22; m 2 ϫ10 3 ; PϽ0.001. No effect was observed after treatment with nonspecific IgG (432Ϯ18 versus control; m 2 ϫ10 3 ; N.S.). Furthermore, collagen content was diminished in animals treated with TWEAK compared with control animals (16.9Ϯ3.7% collagen/intima versus 30.7Ϯ3.58%; PϽ0.05). In addition, a trend to an increase in collagen content was observed in animals treated with anti-TWEAK mAb compared with control animals (37Ϯ5.1% versus 30.7Ϯ3.6%; N.S.). No effect was observed after nonspecific IgG injection (26.3Ϯ2.7% versus control; N.S.).
Moreover, TWEAK injection increased both RANTES and MCP-1 expression in more advanced atherosclerotic plaques compared with control animals (16.1Ϯ3.2 versus 7.8Ϯ1.7; PϽ0.05; 17Ϯ1.4 versus 8.1Ϯ0.7; PϽ0.05, respectively). Treatment with anti-TWEAK alone reduced RANTES and MCP-1 expression in advanced atherosclerotic plaques compared with control animals (3.6Ϯ1.2 versus control; PϽ0.05; 4.4Ϯ0.7 versus control; PϽ0.05; respectively). No effect was observed after nonspecific IgG injection (10.5Ϯ3.9; RAN-TES; 7.8Ϯ0.7; MCP-1) in the expression of both chemokines.
Next, we evaluated macrophages and CD4 ϩ and CD8 ϩ cells in atherosclerotic lesions. TWEAK injection also augmented macrophage infiltration compared with control animals (44.6Ϯ7.7% versus 14.3Ϯ1.6%; PϽ0.01). Furthermore, treatment with anti-TWEAK mAb diminished macrophages compared with control animals (4.9Ϯ0.8% versus 14.3Ϯ1.6%; PϽ0.05). No effect was observed after nonspecific IgG injection (17.6Ϯ2.3% versus control; N.S.). TWEAK treatment also increased the number of CD4 ϩ cells compared with control animals (22.9Ϯ5.3 versus 5.7Ϯ1.3; PϽ0.01; supplemental Figure IIB) . However, treatment with anti-TWEAK alone did not reduce CD4 ϩ cells (5.1Ϯ1.7 versus control; N.S). No effect was observed after nonspecific IgG injection (10.4Ϯ2.2 versus control; N.S). We also have analyzed the number of CD8 ϩ cells in atherosclerotic lesions. No differences were observed in CD8 ϩ positive cells after TWEAK administration. (supplemental Figure IIB) . However, anti-TWEAK diminished the number of CD8 ϩpositive cells (supplemental Figure IIB) . Finally, TWEAK injection also increased NF-B activation compared with control animals (13.4Ϯ0.6 versus 6.1Ϯ1.4%, PϽ0.05) and anti-TWEAK neutralizing antibody diminished NF-B activation (2.6Ϯ0.6 versus control, PϽ0.05; Figure 4 ). Treatment with nonspecific IgG did not modify NF-B activation in mice (5.4Ϯ0.5% versus control; N.S.).
Oxidized-LDL and TWEAK Have a Synergistic Effect on Proinflammatory Cytokine Gene Expression and Secretion in Both VSMCs and MCT Cells
To analyze the effect of TWEAK on proinflammatory cytokine expression, murine VSMCs or MCT cells were cultured in presence of different concentrations of ox-LDL, recombinant TWEAK, or the combination. TWEAK or ox-LDL increased mRNA expression of MCP-1 and RANTES in VSMCs and MCT cells in a time-and dose-dependent manner with a maximal effect at 50 g/mL ox-LDL and 0.1 g/mL TWEAK, as compared with nonstimulated cells (not shown). To test whether ox-LDL and TWEAK has a synergistic effect on proinflammatory gene expression, VSMCs and MCT cells were coincubated simultaneously with both stimuli. As shown in Figure 5A and 5B, the presence of ox-LDL and TWEAK induced a higher MCP-1 and RANTES mRNA expression in VSMCs and MCT cells compared with ox-LDL or TWEAK alone.
Moreover, we observed that both soluble MCP-1 and RANTES were also augmented in a dose-dependent manner in the culture medium from VSMCs and MCT cells after ox-LDL or TWEAK treatment (not shown). In agreement with the results obtained for chemokine gene expression, MCP-1 and RANTES secretion were also increased by the combination of ox-LDL and TWEAK as compared with ox-LDL or TWEAK alone ( Figure 5C and 5D ). In these experimental conditions, anti-TWEAK antibody reversed the proinflammatory response induced by ox-LDL/TWEAK ( Figure 5 ).
Discussion
Although the TWEAK/Fn14 system has been implicated in different pathological situations, the role of TWEAK has not been previously studied in atherosclerosis. The present study is the first to investigate in vivo the effect of short-term administration of TWEAK on atherosclerotic plaque progression and shows that TWEAK exerts a harmful effect increasing lesion size and inflammation in early and advanced lesions and decreasing collagen deposition in advanced lesions. In addition, TWEAK administration exacerbated renal damage associated with hyperlipidemia in ApoE Ϫ/Ϫ mice. Conversely, the involvement of endogenous TWEAK in atherosclerosis was demonstrated by reduced vascular and renal inflammation and injury after short-term treatment with anti-TWEAK neutralizing mAb alone.
TWEAK is a recently characterized member of the TNF superfamily 4 implicated in vascular and acute kidney injury. 14,20 -21 This protein is a multifunctional cytokine that may promote cell proliferation, inflammation, angiogenesis, and cell death. [2] [3] TWEAK and its receptor, Fn14, are expressed by VSMCs, macrophages, and endothelial cells present in human atherosclerotic lesions. 7, [22] [23] Furthermore, potential sources of TWEAK in the kidney include infiltrating monocytes and T lymphocytes, 24 -25 and Fn14 may be expressed by kidney cells 13, 26 in addition to vascular cells and infiltrating monocytes. The biological responses of TWEAK display cell-type specificity and may be influenced by the cell microenvironment. 2 In addition, Fn14 is expressed at low levels in normal healthy tissue and highly inducible in contexts of insult. 3 For this reason, it is necessary to address biological actions of TWEAK in harmful conditions, such as hyperlipidemia.
Atherosclerosis is linked to hypercholesterolemia and the accumulation of inflammatory cells in the artery wall, although the exact mechanisms underlying this process remain unclear. Moreover, abnormal lipid metabolism frequently accompanies and modulates renal disease and is thought to be involved in the pathogenesis of renal injury. 27 In this context, ApoE knockout mice fed on a high-fat diet display a massive triglycerides and cholesterol accumulation, and it is a widely used model to study the effect of early onset hyperlipidemia on vascular wall and on the kidney. 28 -29 The presence of inflammatory cells in atherosclerotic lesions is related to the expression of proinflammatory molecules that contribute to plaque progression. 30 Although adhesion molecules expressed in activated endothelium participate in the anchorage of inflammatory cells and subsequent migration within arterial wall, we have not observed changes in VCAM-1 mRNA expression in the aorta of TWEAK-treated animals compared with control animals (not shown). This is probably because endothelium activation occurs in the initial steps of atherosclerotic plaque development, and these animals were fed with hypercholesterolemic diet during 4 or 10 weeks before TWEAK was injected. In contrast, TWEAK in vivo induced MCP-1 and RANTES expression in both early and advanced atherosclerotic plaques and kidneys of ApoE-knockout mice. MCP-1 and RANTES are chemokines that play an important role in the pathogenesis of atherosclerosis by attracting inflammatory cells to the atherosclerotic plaques 31 and tubulointerstitial lesions in different animal models of renal damage and human renal diseases. 32 Previously it has been reported that TWEAK increases MCP-1 expression in cultured glomerular mesangi-al cells and healthy kidneys 14 as well as MCP-1 secretion in cultured endothelial 5 and VSMCs. 7 These in vitro data are in agreement with our in vivo observation that TWEAK enhanced vascular and renal inflammation. The expression of several proinflammatory molecules, including MCP-1 and RANTES, are controlled by the transcription factor NF-B. 33 Activated NF-B has been detected in human atherosclerotic plaques in the nuclei of macrophages and VSMCs, 34 participating in dysregulation of VSMCs in human atherosclerosis. 33 Moreover, different studies have demonstrated that a variety of stimuli may induce NF-B also in renal resident cells, showing the central role of NF-B in the pathogenesis of renal diseases. 35 In this context, we suggest that this nuclear factor could be mediating TWEAK-induced inflammation, because a higher expression of NF-B activation was observed after TWEAK injection in both vascular and renal lesions. The NF-B activation and chemokine expression elicited by TWEAK in vivo correlated with an augmentation of inflammatory cells observed in both vascular and renal lesions. Furthermore, TWEAK injection decreased collagen content in advanced atherosclerotic lesions, indicating that TWEAK not only increased inflammatory response in ApoE Ϫ/Ϫ mice but may also augment plaque instability.
OxLDL plays an important role in the progression of both atherosclerosis and renal injury 36 throughout induction of inflammation and apoptosis, processes relevant for the progression of atherosclerotic lesions. 37 Moreover, oxLDL may affect the behavior of endothelial, mesangial, tubular epithelial cells, and podocytes. 38 -40 To our knowledge, there was no previous study showing an inflammatory effect induced by TWEAK in the context of oxLDL on vascular and renal tubular epithelial cells. Consistent with the in vivo data, we found that recombinant TWEAK or ox-LDL increase MCP-1 and RANTES expression and secretion by both VSMCs and MCT cells. Furthermore, incubation with both stimuli induced a synergistic effect on chemokines expression. Thus, it is possible that the increment of chemokines expression and macrophage infiltration observed in atherosclerotic plaques and renal lesions of mice was due to a cooperative effect of TWEAK with the hyperlipidemic diet.
Although we cannot exclude additional effects of TWEAK on other organs systems that might indirectly promote renal or arterial injury, the fact that TWEAK has similar actions in vitro and in vivo on renal and vascular cells supports the notion that TWEAK has direct effects on these cells in vivo.
Finally, treatment with anti-TWEAK mAb alone reduced macrophage accumulation, proinflammatory cytokine expression, and NF-B activation, implicating a pathological role for endogenous TWEAK. These results suggest that TWEAK may be a therapeutic target to prevent vascular and renal damage associated to hyperlipidemia.
In summary, TWEAK enhances vascular lesions and renal damage associated with hyperlipidemic state by exacerbating secretion of proinflammatory cytokines and macrophage cell recruitment. These actions may be mediated by NF-B activation. More studies are warranted to evaluate whether TWEAK may be a novel therapeutic target to prevent vascular and renal damage associated to hyperlipidemia.
